《接受血液透析患者中新型羟基磷灰石结晶抑制剂SNF472的作用——CALIPSO试验的亚组分析》勘误。《肾脏病国际报告》2020年；5：2178 - 2182。
Erratum to "Effects of SNF472, a Novel Inhibitor of Hydroxyapatite Crystallization in Patients Receiving Hemodialysis - Subgroup Analyses of the CALIPSO Trial." Kidney Int. Rep. 2020;5:2178-2182.
出版信息
Kidney Int Rep. 2021 Mar 5;6(4):1196. doi: 10.1016/j.ekir.2021.02.021. eCollection 2021 Apr.
Abstract
[This corrects the article DOI: 10.1016/j.ekir.2020.09.032.].
摘要
[本文更正了文章的数字对象标识符：10.1016/j.ekir.2020.09.032。]
相似文献
1
Erratum to "Effects of SNF472, a Novel Inhibitor of Hydroxyapatite Crystallization in Patients Receiving Hemodialysis - Subgroup Analyses of the CALIPSO Trial." Kidney Int. Rep. 2020;5:2178-2182.《接受血液透析患者中新型羟基磷灰石结晶抑制剂SNF472的作用——CALIPSO试验的亚组分析》勘误。《肾脏病国际报告》2020年；5：2178 - 2182。
Kidney Int Rep. 2021 Mar 5;6(4):1196. doi: 10.1016/j.ekir.2021.02.021. eCollection 2021 Apr.
2
Effects of SNF472, a Novel Inhibitor of Hydroxyapatite Crystallization in Patients Receiving Hemodialysis - Subgroup Analyses of the CALIPSO Trial.SNF472（一种新型羟基磷灰石结晶抑制剂）对接受血液透析患者的影响——CALIPSO试验的亚组分析
Kidney Int Rep. 2020 Nov 4;5(12):2178-2182. doi: 10.1016/j.ekir.2020.09.032. eCollection 2020 Dec.
3
Corrigendum to "The Cumulative Rate of SARS-CoV-2 Infection in Chinese Hemodialysis Patients" [Kidney Int. Rep. 2020 1416-1421].《中国血液透析患者中 SARS-CoV-2 感染的累积率》[《肾脏国际报告》2020 年第 1416 - 1421 页]勘误
Kidney Int Rep. 2021 Sep;6(9):2525. doi: 10.1016/j.ekir.2021.07.021. Epub 2021 Sep 2.
4
Erratum to "Randomized Trial of Acute Changes in Plasma Phosphate After Phosphorus-Standardized Meals in Peritoneal Dialysis" 2021;6:304-312.《腹膜透析中磷标准化餐后血浆磷急性变化的随机试验》勘误 2021年；6:304 - 312。
Kidney Int Rep. 2021 Mar 11;6(5):1486. doi: 10.1016/j.ekir.2021.03.872. eCollection 2021 May.
5
Erratum to "Perrone RD, Chapman AB, Oberdhan D, et al. The NOCTURNE Randomized Trial Comparing 2 Tolvaptan Formulations." . 2020;5:801-812.《“佩罗内RD、查普曼AB、奥伯丹D等人。比较两种托伐普坦制剂的夜尿症随机试验”》勘误。2020年；5：801 - 812。
Kidney Int Rep. 2020 Dec 2;5(12):2407-2408. doi: 10.1016/j.ekir.2020.11.011. eCollection 2020 Dec.
6
Erratum: SAT-337 Acute kidney injury in patients with solid organ and haematological malignancies: a single centre experience. . 2019;4:S149.勘误：实体器官和血液系统恶性肿瘤患者的急性肾损伤：单中心经验。. 2019；4：S149。
Kidney Int Rep. 2019 Oct 2;4(10):1513. doi: 10.1016/j.ekir.2019.08.008. eCollection 2019 Oct.
7
Corrigendum to Inaba M, Une Y, Ikejiri K, et al. "Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japan-A Phase 2 Randomized Trial." . 2022;7:177-188.稻叶真人、宇根洋、池尻健等所著《日本接受血液透析的高磷血症患者中替那帕诺的剂量反应——一项2期随机试验》的勘误。2022年；7：177 - 188。
Kidney Int Rep. 2022 Jul 5;7(7):1729. doi: 10.1016/j.ekir.2022.06.008. eCollection 2022 Jul.
8
Corrigendum to "Efficacy of evocalcet in previously cinacalcet-treated secondary hyperparathyroidism patients," [ 2021; https://doi.org/10.1016/j.ekir.2021.08.020].《依那卡塞在曾接受西那卡塞治疗的继发性甲状旁腺功能亢进患者中的疗效》勘误，[2021年；https://doi.org/10.1016/j.ekir.2021.08.020] 。
Kidney Int Rep. 2021 Nov 5;6(11):2936-2937. doi: 10.1016/j.ekir.2021.09.011. eCollection 2021 Nov.
9
Erratum: Ganesh K, Nair RR, Kurian G, et al. Posterior reversible encephalopathy syndrome in kidney disease. . 2018;3:502-507.勘误：加内什·K、奈尔·RR、库里安·G等。肾病中的后部可逆性脑病综合征。. 2018年；3：502 - 507。
Kidney Int Rep. 2018 Mar 22;3(3):765. doi: 10.1016/j.ekir.2018.03.007. eCollection 2018 May.
10
Erratum: Evans M, Grams ME, Sang Y, et al., for the Chronic Kidney Disease Prognosis Consortium. Risk factors for prognosis in patients with severely decreased GFR. . 2018;3:625-637.勘误：埃文斯 M、格兰姆斯 ME、桑 Y 等，代表慢性肾脏病预后联盟。估算肾小球滤过率严重降低患者的预后危险因素。《……》2018 年；3：625 - 637。 （原文中“.”处信息缺失，以上是根据完整格式要求尽量完整的翻译内容）
Kidney Int Rep. 2018 Aug 30;3(6):1506. doi: 10.1016/j.ekir.2018.08.009. eCollection 2018 Nov.
Zotero 插件